Details of the Drug

General Information of Drug (ID: DM3JDRP)

Drug Name
Cladribine
Synonyms
Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
Indication
Disease Entry ICD 11 Status REF
Hairy cell leukaemia 2A82.2 Approved [1]
Multiple sclerosis 8A40 Phase 3 [2]
Relapsing-remitting multiple sclerosis 8A40.0 Phase 3 [3]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.69
Logarithm of the Partition Coefficient (xlogp) 0.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 34-48% []
Clearance
The clearance of drug is 978 +/- 422 mL/h/kg []
Elimination
18% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.4 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.31502 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.79% [5]
Vd
The volume of distribution (Vd) of drug is 9 L/kg []
Chemical Identifiers
Formula
C10H12ClN5O3
IUPAC Name
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
Canonical SMILES
C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
InChI
InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey
PTOAARAWEBMLNO-KVQBGUIXSA-N
Cross-matching ID
PubChem CID
20279
ChEBI ID
CHEBI:567361
CAS Number
4291-63-8
DrugBank ID
DB00242
TTD ID
D05GJW
VARIDT ID
DR00087
INTEDE ID
DR1918
ACDINA ID
D00951
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Equilibrative nucleoside transporter 3 (SLC29A3) DTZAWTH S29A3_HUMAN Substrate [8]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Deoxycytidine kinase (DCK)
Main DME 		DE9FGNK DCK_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [12]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [13]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Gene/Protein Processing [13]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [14]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Gene/Protein Processing [13]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [13]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [15]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [16]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Gene/Protein Processing [16]
Histone-lysine N-methyltransferase 2A (KMT2A) OT9GLJI6 KMT2A_HUMAN Drug Response [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cladribine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentostatin DM0HXDS Major Additive myelosuppressive effects by the combination of Cladribine and Pentostatin. Mature B-cell leukaemia [2A82] [18]
Ofatumumab DM295PR Major Additive myelosuppressive effects by the combination of Cladribine and Ofatumumab. Mature B-cell leukaemia [2A82] [18]
Obinutuzumab DM3BVAE Major Additive immunosuppressive effects by the combination of Cladribine and Obinutuzumab. Mature B-cell leukaemia [2A82] [18]
Idelalisib DM602WT Major Additive myelosuppressive effects by the combination of Cladribine and Idelalisib. Mature B-cell leukaemia [2A82] [18]
GDC-0199 DMH0QKA Major Additive immunosuppressive effects by the combination of Cladribine and GDC-0199. Mature B-cell leukaemia [2A82] [18]
Chlorambucil DMRKE63 Major Additive myelosuppressive effects by the combination of Cladribine and Chlorambucil. Mature B-cell leukaemia [2A82] [18]
IPI-145 DMWA24P Major Additive myelosuppressive effects by the combination of Cladribine and IPI-145. Mature B-cell leukaemia [2A82] [18]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Cladribine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Thioguanine DM7NKEV Major Additive immunosuppressive effects by the combination of Cladribine and Thioguanine. Acute myeloid leukaemia [2A60] [18]
Uracil mustard DMHL7OB Major Additive immunosuppressive effects by the combination of Cladribine and Uracil mustard. Acute myeloid leukaemia [2A60] [18]
Midostaurin DMI6E0R Major Additive myelosuppressive effects by the combination of Cladribine and Midostaurin. Acute myeloid leukaemia [2A60] [18]
Idarubicin DMM0XGL Major Additive myelosuppressive effects by the combination of Cladribine and Idarubicin. Acute myeloid leukaemia [2A60] [18]
Daunorubicin DMQUSBT Major Additive myelosuppressive effects by the combination of Cladribine and Daunorubicin. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Cladribine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [19]
Siltuximab DMGEATB Major Additive immunosuppressive effects by the combination of Cladribine and Siltuximab. Anemia [3A00-3A9Z] [18]
Nifedipine DMSVOZT Moderate Decreased clearance of Cladribine due to the transporter inhibition by Nifedipine. Angina pectoris [BA40] [19]
Cilostazol DMZMSCT Moderate Decreased clearance of Cladribine due to the transporter inhibition by Cilostazol. Arterial occlusive disease [BD40] [19]
Budesonide DMJIBAW Major Additive immunosuppressive effects by the combination of Cladribine and Budesonide. Asthma [CA23] [18]
Roflumilast DMPGHY8 Major Additive immunosuppressive effects by the combination of Cladribine and Roflumilast. Asthma [CA23] [18]
Dupilumab DMOAD2Y Major Additive immunosuppressive effects by the combination of Cladribine and Dupilumab. Atopic eczema [EA80] [18]
Chloramphenicol DMFXEWT Major Additive immunosuppressive effects by the combination of Cladribine and Chloramphenicol. Bacterial infection [1A00-1C4Z] [18]
Linezolid DMGFPU2 Major Additive myelosuppressive effects by the combination of Cladribine and Linezolid. Bacterial infection [1A00-1C4Z] [18]
Ag-221 DMS0ZBI Moderate Decreased clearance of Cladribine due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [19]
Valrubicin DMOYJFK Major Additive immunosuppressive effects by the combination of Cladribine and Valrubicin. Bladder cancer [2C94] [18]
Temozolomide DMKECZD Major Additive myelosuppressive effects by the combination of Cladribine and Temozolomide. Brain cancer [2A00] [18]
Lomustine DMMWSUL Major Additive myelosuppressive effects by the combination of Cladribine and Lomustine. Brain cancer [2A00] [18]
Eribulin DM1DX4Q Major Additive immunosuppressive effects by the combination of Cladribine and Eribulin. Breast cancer [2C60-2C6Y] [18]
Talazoparib DM1KS78 Major Additive myelosuppressive effects by the combination of Cladribine and Talazoparib. Breast cancer [2C60-2C6Y] [18]
Ixabepilone DM2OZ3G Major Additive immunosuppressive effects by the combination of Cladribine and Ixabepilone. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Major Additive immunosuppressive effects by the combination of Cladribine and LY2835219. Breast cancer [2C60-2C6Y] [18]
Pralatrexate DMAO80I Major Additive myelosuppressive effects by the combination of Cladribine and Pralatrexate. Breast cancer [2C60-2C6Y] [18]
Palbociclib DMD7L94 Major Additive myelosuppressive effects by the combination of Cladribine and Palbociclib. Breast cancer [2C60-2C6Y] [18]
Mitomycin DMH0ZJE Major Additive immunosuppressive effects by the combination of Cladribine and Mitomycin. Breast cancer [2C60-2C6Y] [18]
Thiotepa DMIZKOP Major Additive myelosuppressive effects by the combination of Cladribine and Thiotepa. Breast cancer [2C60-2C6Y] [18]
Cabazitaxel DMPAZHC Major Additive myelosuppressive effects by the combination of Cladribine and Cabazitaxel. Breast cancer [2C60-2C6Y] [18]
Bosutinib DMTI8YE Major Additive myelosuppressive effects by the combination of Cladribine and Bosutinib. Breast cancer [2C60-2C6Y] [18]
Corticotropin DMP9TWZ Major Additive immunosuppressive effects by the combination of Cladribine and Corticotropin. Chronic kidney disease [GB61] [18]
PF-04449913 DMSB068 Moderate Decreased clearance of Cladribine due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [18]
Phenylbutazone DMAYL0T Major Additive immunosuppressive effects by the combination of Cladribine and Phenylbutazone. Chronic pain [MG30] [18]
Irinotecan DMP6SC2 Major Additive myelosuppressive effects by the combination of Cladribine and Irinotecan. Colorectal cancer [2B91] [18]
Oxaliplatin DMQNWRD Major Additive immunosuppressive effects by the combination of Cladribine and Oxaliplatin. Colorectal cancer [2B91] [18]
Aflibercept DMT3D5I Major Additive immunosuppressive effects by the combination of Cladribine and Aflibercept. Colorectal cancer [2B91] [18]
Capecitabine DMTS85L Major Additive myelosuppressive effects by the combination of Cladribine and Capecitabine. Colorectal cancer [2B91] [18]
Nimodipine DMQ0RKZ Moderate Decreased clearance of Cladribine due to the transporter inhibition by Nimodipine. Coronary vasospastic disease [BA85] [19]
Mycophenolic acid DMRBMAU Major Additive myelosuppressive effects by the combination of Cladribine and Mycophenolic acid. Crohn disease [DD70] [18]
Polatuzumab vedotin DMF6Y0L Major Additive immunosuppressive effects by the combination of Cladribine and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [18]
Axicabtagene ciloleucel DMYHN59 Major Additive immunosuppressive effects by the combination of Cladribine and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [18]
Flucytosine DM13VTW Major Additive myelosuppressive effects by the combination of Cladribine and Flucytosine. Endocarditis [BB40-BA42] [18]
Felbamate DM1V5ZS Major Additive immunosuppressive effects by the combination of Cladribine and Felbamate. Epilepsy/seizure [8A61-8A6Z] [18]
Mephenytoin DM5UGDK Major Additive immunosuppressive effects by the combination of Cladribine and Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [18]
Paramethadione DMR5ZUP Major Additive immunosuppressive effects by the combination of Cladribine and Paramethadione. Epilepsy/seizure [8A61-8A6Z] [18]
Ethotoin DMXWOCP Major Additive immunosuppressive effects by the combination of Cladribine and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [18]
Carbamazepine DMZOLBI Major Additive immunosuppressive effects by the combination of Cladribine and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [18]
Bay 80-6946 DMLOS5R Major Additive immunosuppressive effects by the combination of Cladribine and Bay 80-6946. Follicular lymphoma [2A80] [18]
Pentamidine DMHZJCG Major Additive immunosuppressive effects by the combination of Cladribine and Pentamidine. Fungal infection [1F29-1F2F] [18]
Avapritinib DMK2GZX Major Additive immunosuppressive effects by the combination of Cladribine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [18]
Colchicine DM2POTE Major Additive myelosuppressive effects by the combination of Cladribine and Colchicine. Gout [FA25] [18]
177Lu-DOTATATE DMT8GVU Major Additive immunosuppressive effects by the combination of Cladribine and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [18]
Procarbazine DMIK367 Major Additive immunosuppressive effects by the combination of Cladribine and Procarbazine. Hodgkin lymphoma [2B30] [18]
Bleomycin DMNER5S Major Additive immunosuppressive effects by the combination of Cladribine and Bleomycin. Hodgkin lymphoma [2B30] [18]
Brentuximab vedotin DMWLC57 Major Additive myelosuppressive effects by the combination of Cladribine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [18]
Zidovudine DM4KI7O Major Additive immunosuppressive effects by the combination of Cladribine and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [18]
Fostemsavir DM50ILT Moderate Decreased clearance of Cladribine due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [20]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Cladribine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [18]
Dipyridamole DMXY30O Moderate Decreased clearance of Cladribine due to the transporter inhibition by Dipyridamole. Hypertension [BA00-BA04] [19]
Fludrocortisone DMUDIR8 Major Additive immunosuppressive effects by the combination of Cladribine and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [18]
Auranofin DMWE2N4 Major Additive myelosuppressive effects by the combination of Cladribine and Auranofin. Inflammatory arthropathy [FA2Z] [18]
Olaratumab DMNYOIX Major Additive immunosuppressive effects by the combination of Cladribine and Olaratumab. Kaposi sarcoma [2B57] [18]
Methotrexate DM2TEOL Major Additive myelosuppressive effects by the combination of Cladribine and Methotrexate. Leukaemia [2A60-2B33] [18]
Nelarabine DMB6VEG Major Additive myelosuppressive effects by the combination of Cladribine and Nelarabine. Leukaemia [2A60-2B33] [18]
DTI-015 DMXZRW0 Major Additive myelosuppressive effects by the combination of Cladribine and DTI-015. Liver cancer [2C12] [18]
Denosumab DMNI0KO Major Additive immunosuppressive effects by the combination of Cladribine and Denosumab. Low bone mass disorder [FB83] [18]
Brigatinib DM7W94S Major Additive immunosuppressive effects by the combination of Cladribine and Brigatinib. Lung cancer [2C25] [18]
Lurbinectedin DMEFRTZ Major Additive immunosuppressive effects by the combination of Cladribine and Lurbinectedin. Lung cancer [2C25] [18]
Osimertinib DMRJLAT Major Additive immunosuppressive effects by the combination of Cladribine and Osimertinib. Lung cancer [2C25] [18]
Capmatinib DMYCXKL Moderate Decreased clearance of Cladribine due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [21]
Belimumab DM3OBQF Major Additive immunosuppressive effects by the combination of Cladribine and Belimumab. Lupus erythematosus [4A40] [18]
Primaquine DMWQ16I Major Additive myelosuppressive effects by the combination of Cladribine and Primaquine. Malaria [1F40-1F45] [18]
Inotuzumab ozogamicin DMAC130 Major Additive myelosuppressive effects by the combination of Cladribine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [18]
Fludarabine DMVRLT7 Major Additive myelosuppressive effects by the combination of Cladribine and Fludarabine. Malignant haematopoietic neoplasm [2B33] [18]
Acalabrutinib DM7GCVW Major Additive myelosuppressive effects by the combination of Cladribine and Acalabrutinib. Mature B-cell lymphoma [2A85] [18]
Clofarabine DMCVJ86 Major Additive myelosuppressive effects by the combination of Cladribine and Clofarabine. Mature B-cell lymphoma [2A85] [18]
Blinatumomab DMGECIJ Major Additive myelosuppressive effects by the combination of Cladribine and Blinatumomab. Mature B-cell lymphoma [2A85] [18]
Ibrutinib DMHZCPO Major Additive myelosuppressive effects by the combination of Cladribine and Ibrutinib. Mature B-cell lymphoma [2A85] [18]
Vincristine DMINOX3 Major Additive myelosuppressive effects by the combination of Cladribine and Vincristine. Mature B-cell lymphoma [2A85] [18]
Teniposide DMLW57T Major Additive immunosuppressive effects by the combination of Cladribine and Teniposide. Mature B-cell lymphoma [2A85] [18]
Tisagenlecleucel DMM9BJD Major Additive immunosuppressive effects by the combination of Cladribine and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [18]
Mercaptopurine DMTM2IK Major Additive myelosuppressive effects by the combination of Cladribine and Mercaptopurine. Mature B-cell lymphoma [2A85] [18]
Ponatinib DMYGJQO Major Additive myelosuppressive effects by the combination of Cladribine and Ponatinib. Mature B-cell lymphoma [2A85] [18]
Cytarabine DMZD5QR Major Additive myelosuppressive effects by the combination of Cladribine and Cytarabine. Mature B-cell lymphoma [2A85] [18]
Mechlorethamine DM0CVXA Major Additive immunosuppressive effects by the combination of Cladribine and Mechlorethamine. Mature T-cell lymphoma [2A90] [18]
Dacarbazine DMNPZL4 Major Additive myelosuppressive effects by the combination of Cladribine and Dacarbazine. Melanoma [2C30] [18]
Lasmiditan DMXLVDT Moderate Decreased clearance of Cladribine due to the transporter inhibition by Lasmiditan. Migraine [8A80] [22]
Carfilzomib DM48K0X Major Additive immunosuppressive effects by the combination of Cladribine and Carfilzomib. Multiple myeloma [2A83] [18]
Panobinostat DM58WKG Major Additive myelosuppressive effects by the combination of Cladribine and Panobinostat. Multiple myeloma [2A83] [18]
Lenalidomide DM6Q7U4 Major Additive myelosuppressive effects by the combination of Cladribine and Lenalidomide. Multiple myeloma [2A83] [18]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Cladribine and Thalidomide. Multiple myeloma [2A83] [23]
Selinexor DMBD4K3 Major Additive myelosuppressive effects by the combination of Cladribine and Selinexor. Multiple myeloma [2A83] [18]
Belantamab mafodotin DMBT3AI Major Additive immunosuppressive effects by the combination of Cladribine and Belantamab mafodotin. Multiple myeloma [2A83] [18]
Elotuzumab DMEYHG9 Major Additive immunosuppressive effects by the combination of Cladribine and Elotuzumab. Multiple myeloma [2A83] [18]
Daratumumab DMKCIUZ Major Additive myelosuppressive effects by the combination of Cladribine and Daratumumab. Multiple myeloma [2A83] [18]
Melphalan DMOLNHF Major Additive myelosuppressive effects by the combination of Cladribine and Melphalan. Multiple myeloma [2A83] [18]
Tecfidera DM2OVDT Major Additive immunosuppressive effects by the combination of Cladribine and Tecfidera. Multiple sclerosis [8A40] [18]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Cladribine and Siponimod. Multiple sclerosis [8A40] [19]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Cladribine and Fingolimod. Multiple sclerosis [8A40] [24]
Ocrelizumab DMEZ2KH Major Additive immunosuppressive effects by the combination of Cladribine and Ocrelizumab. Multiple sclerosis [8A40] [18]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Cladribine and Ozanimod. Multiple sclerosis [8A40] [18]
Deflazacort DMV0RNS Major Additive immunosuppressive effects by the combination of Cladribine and Deflazacort. Muscular dystrophy [8C70] [18]
Bexarotene DMOBIKY Major Additive immunosuppressive effects by the combination of Cladribine and Bexarotene. Mycosis fungoides [2B01] [18]
Romidepsin DMT5GNL Major Additive immunosuppressive effects by the combination of Cladribine and Romidepsin. Mycosis fungoides [2B01] [18]
Decitabine DMQL8XJ Major Additive immunosuppressive effects by the combination of Cladribine and Decitabine. Myelodysplastic syndrome [2A37] [18]
Azacitidine DMTA5OE Major Additive myelosuppressive effects by the combination of Cladribine and Azacitidine. Myelodysplastic syndrome [2A37] [18]
Nilotinib DM7HXWT Major Additive myelosuppressive effects by the combination of Cladribine and Nilotinib. Myeloproliferative neoplasm [2A20] [18]
Ruxolitinib DM7Q98D Major Additive myelosuppressive effects by the combination of Cladribine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [18]
Imatinib DM7RJXL Major Additive immunosuppressive effects by the combination of Cladribine and Imatinib. Myeloproliferative neoplasm [2A20] [18]
Dasatinib DMJV2EK Major Additive myelosuppressive effects by the combination of Cladribine and Dasatinib. Myeloproliferative neoplasm [2A20] [18]
Hydroxyurea DMOQVU9 Major Additive myelosuppressive effects by the combination of Cladribine and Hydroxyurea. Myeloproliferative neoplasm [2A20] [18]
Omacetaxine mepesuccinate DMPU2WX Major Additive immunosuppressive effects by the combination of Cladribine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [18]
Busulfan DMXYJ9C Major Additive myelosuppressive effects by the combination of Cladribine and Busulfan. Myeloproliferative neoplasm [2A20] [18]
Inebilizumab DMI0RHA Major Additive immunosuppressive effects by the combination of Cladribine and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [18]
Atezolizumab DMMF8U0 Major Additive immunosuppressive effects by the combination of Cladribine and Atezolizumab. Non-small cell lung cancer [2C25] [18]
Olaparib DM8QB1D Major Additive immunosuppressive effects by the combination of Cladribine and Olaparib. Ovarian cancer [2C73] [18]
Rucaparib DM9PVX8 Major Additive myelosuppressive effects by the combination of Cladribine and Rucaparib. Ovarian cancer [2C73] [18]
Carboplatin DMG281S Major Additive myelosuppressive effects by the combination of Cladribine and Carboplatin. Ovarian cancer [2C73] [18]
Altretamine DMKLAYG Major Additive immunosuppressive effects by the combination of Cladribine and Altretamine. Ovarian cancer [2C73] [18]
MK-4827 DMLYGH4 Major Additive myelosuppressive effects by the combination of Cladribine and MK-4827. Ovarian cancer [2C73] [18]
Trimethadione DM0Q8MZ Major Additive immunosuppressive effects by the combination of Cladribine and Trimethadione. Pancreatic cancer [2C10] [18]
Streptozocin DMOF7AT Major Additive immunosuppressive effects by the combination of Cladribine and Streptozocin. Pancreatic cancer [2C10] [18]
Levamisole DM5EN79 Major Additive immunosuppressive effects by the combination of Cladribine and Levamisole. Parasitic infection [1D0Y-1G2Z] [18]
Albendazole DMYZ57N Major Additive myelosuppressive effects by the combination of Cladribine and Albendazole. Parasitic worm infestation [1F90] [18]
Pemetrexed DMMX2E6 Major Additive immunosuppressive effects by the combination of Cladribine and Pemetrexed. Pleural mesothelioma [2C26] [18]
Dapsone DM4LT8A Major Additive myelosuppressive effects by the combination of Cladribine and Dapsone. Pneumonia [CA40] [18]
Prednisone DM2HG4X Major Additive immunosuppressive effects by the combination of Cladribine and Prednisone. Postoperative inflammation [1A00-CA43] [18]
Betamethasone DMAHJEF Major Additive immunosuppressive effects by the combination of Cladribine and Betamethasone. Postoperative inflammation [1A00-CA43] [18]
Hydrocortisone DMGEMB7 Major Additive immunosuppressive effects by the combination of Cladribine and Hydrocortisone. Postoperative inflammation [1A00-CA43] [18]
Lonafarnib DMGM2Z6 Moderate Decreased clearance of Cladribine due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [25]
Darolutamide DMV7YFT Moderate Decreased clearance of Cladribine due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [26]
Brodalumab DMASDQ6 Major Additive immunosuppressive effects by the combination of Cladribine and Brodalumab. Psoriasis [EA90] [18]
Ustekinumab DMHTYK3 Major Additive immunosuppressive effects by the combination of Cladribine and Ustekinumab. Psoriasis [EA90] [18]
Tildrakizumab DMLW9HG Major Additive immunosuppressive effects by the combination of Cladribine and Tildrakizumab. Psoriasis [EA90] [18]
Risankizumab DMM32GT Major Additive immunosuppressive effects by the combination of Cladribine and Risankizumab. Psoriasis [EA90] [18]
Ixekizumab DMXW92T Major Additive immunosuppressive effects by the combination of Cladribine and Ixekizumab. Psoriasis [EA90] [18]
Everolimus DM8X2EH Major Additive immunosuppressive effects by the combination of Cladribine and Everolimus. Renal cell carcinoma [2C90] [18]
Temsirolimus DMS104F Major Additive immunosuppressive effects by the combination of Cladribine and Temsirolimus. Renal cell carcinoma [2C90] [18]
Ciclesonide DM2NA4K Major Additive immunosuppressive effects by the combination of Cladribine and Ciclesonide. Respiratory system disease [CB40-CB7Z] [18]
Sulindac DM2QHZU Moderate Decreased clearance of Cladribine due to the transporter inhibition by Sulindac. Rheumatoid arthritis [FA20] [19]
Upadacitinib DM32B5U Major Additive immunosuppressive effects by the combination of Cladribine and Upadacitinib. Rheumatoid arthritis [FA20] [18]
Penicillamine DM40EF6 Major Additive myelosuppressive effects by the combination of Cladribine and Penicillamine. Rheumatoid arthritis [FA20] [18]
Baricitinib DM4ONW5 Major Additive immunosuppressive effects by the combination of Cladribine and Baricitinib. Rheumatoid arthritis [FA20] [18]
Tocilizumab DM7J6OR Major Additive immunosuppressive effects by the combination of Cladribine and Tocilizumab. Rheumatoid arthritis [FA20] [18]
Canakinumab DM8HLO5 Major Additive immunosuppressive effects by the combination of Cladribine and Canakinumab. Rheumatoid arthritis [FA20] [18]
Tofacitinib DMBS370 Major Additive immunosuppressive effects by the combination of Cladribine and Tofacitinib. Rheumatoid arthritis [FA20] [18]
Rilonacept DMGLUQS Major Additive immunosuppressive effects by the combination of Cladribine and Rilonacept. Rheumatoid arthritis [FA20] [18]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Cladribine and Golimumab. Rheumatoid arthritis [FA20] [18]
Dexamethasone DMMWZET Major Additive immunosuppressive effects by the combination of Cladribine and Dexamethasone. Rheumatoid arthritis [FA20] [18]
Sarilumab DMOGNXY Major Additive immunosuppressive effects by the combination of Cladribine and Sarilumab. Rheumatoid arthritis [FA20] [18]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Cladribine and Leflunomide. Rheumatoid arthritis [FA20] [18]
Abatacept DMSA8RU Major Additive immunosuppressive effects by the combination of Cladribine and Abatacept. Rheumatoid arthritis [FA20] [18]
Clozapine DMFC71L Major Additive myelosuppressive effects by the combination of Cladribine and Clozapine. Schizophrenia [6A20] [18]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Cladribine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [27]
Mogamulizumab DMISH0Z Major Additive immunosuppressive effects by the combination of Cladribine and Mogamulizumab. Sezary syndrome [2B02] [18]
Tedizolid DMG2SKR Moderate Decreased clearance of Cladribine due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [18]
Floxuridine DM04LR2 Major Additive myelosuppressive effects by the combination of Cladribine and Floxuridine. Solid tumour/cancer [2A00-2F9Z] [18]
Dactinomycin DM2YGNW Major Additive immunosuppressive effects by the combination of Cladribine and Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [18]
Methylprednisolone DM4BDON Major Additive immunosuppressive effects by the combination of Cladribine and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [18]
Cyclophosphamide DM4O2Z7 Major Additive immunosuppressive effects by the combination of Cladribine and Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [18]
Vinblastine DM5TVS3 Major Additive immunosuppressive effects by the combination of Cladribine and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [18]
PDX-101 DM6OC53 Major Additive myelosuppressive effects by the combination of Cladribine and PDX-101. Solid tumour/cancer [2A00-2F9Z] [18]
Ifosfamide DMCT3I8 Major Additive myelosuppressive effects by the combination of Cladribine and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [18]
Docetaxel DMDI269 Major Additive immunosuppressive effects by the combination of Cladribine and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [18]
Trabectedin DMG3Y89 Major Additive myelosuppressive effects by the combination of Cladribine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [18]
Mitoxantrone DMM39BF Major Additive immunosuppressive effects by the combination of Cladribine and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [18]
LEE011 DMMX75K Major Additive myelosuppressive effects by the combination of Cladribine and LEE011. Solid tumour/cancer [2A00-2F9Z] [18]
Etoposide DMNH3PG Major Additive myelosuppressive effects by the combination of Cladribine and Etoposide. Solid tumour/cancer [2A00-2F9Z] [18]
Epirubicin DMPDW6T Major Additive immunosuppressive effects by the combination of Cladribine and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [18]
Prednisolone DMQ8FR2 Major Additive immunosuppressive effects by the combination of Cladribine and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [18]
Cisplatin DMRHGI9 Major Additive immunosuppressive effects by the combination of Cladribine and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [18]
Gemcitabine DMSE3I7 Major Additive myelosuppressive effects by the combination of Cladribine and Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [18]
Fluorouracil DMUM7HZ Major Additive myelosuppressive effects by the combination of Cladribine and Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [18]
Taxol DMUOT9V Major Additive myelosuppressive effects by the combination of Cladribine and Taxol. Solid tumour/cancer [2A00-2F9Z] [18]
Doxorubicin DMVP5YE Major Additive immunosuppressive effects by the combination of Cladribine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [18]
Vinorelbine DMVXFYE Major Additive myelosuppressive effects by the combination of Cladribine and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [18]
Pomalidomide DMTGBAX Major Additive myelosuppressive effects by the combination of Cladribine and Pomalidomide. Systemic sclerosis [4A42] [18]
Plicamycin DM7C8YV Major Additive myelosuppressive effects by the combination of Cladribine and Plicamycin. Testicular cancer [2C80] [18]
Eltrombopag DMOGFIX Moderate Decreased clearance of Cladribine due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [19]
Trimetrexate DMDEA85 Major Additive immunosuppressive effects by the combination of Cladribine and Trimetrexate. Toxoplasmosis [1F57] [18]
Sirolimus DMGW1ID Major Additive myelosuppressive effects by the combination of Cladribine and Sirolimus. Transplant rejection [NE84] [18]
Azathioprine DMMZSXQ Major Additive immunosuppressive effects by the combination of Cladribine and Azathioprine. Transplant rejection [NE84] [18]
Mycophenolate mofetil DMPQAGE Major Additive myelosuppressive effects by the combination of Cladribine and Mycophenolate mofetil. Transplant rejection [NE84] [18]
Belatacept DMXLYQF Major Additive immunosuppressive effects by the combination of Cladribine and Belatacept. Transplant rejection [NE84] [18]
Tacrolimus DMZ7XNQ Major Additive immunosuppressive effects by the combination of Cladribine and Tacrolimus. Transplant rejection [NE84] [18]
Durvalumab DM4PVDY Major Additive immunosuppressive effects by the combination of Cladribine and Durvalumab. Ureteral cancer [2C92] [18]
Acetohydroxamic Acid DMYX7NI Major Additive immunosuppressive effects by the combination of Cladribine and Acetohydroxamic Acid. Urinary tract infection [GC08] [18]
Triamcinolone DM98IXF Major Additive immunosuppressive effects by the combination of Cladribine and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [18]
Fluticasone DMGCSVF Major Additive immunosuppressive effects by the combination of Cladribine and Fluticasone. Vasomotor/allergic rhinitis [CA08] [18]
Procainamide DMNMXR8 Major Additive immunosuppressive effects by the combination of Cladribine and Procainamide. Ventricular tachyarrhythmia [BC71] [18]
Tocainide DMYNMDP Major Additive immunosuppressive effects by the combination of Cladribine and Tocainide. Ventricular tachyarrhythmia [BC71] [18]
Ganciclovir DM1MBYQ Major Additive immunosuppressive effects by the combination of Cladribine and Ganciclovir. Virus infection [1A24-1D9Z] [18]
Trifluridine DMG2YBD Major Additive immunosuppressive effects by the combination of Cladribine and Trifluridine. Virus infection [1A24-1D9Z] [18]
Valganciclovir DMS2IUH Major Additive immunosuppressive effects by the combination of Cladribine and Valganciclovir. Virus infection [1A24-1D9Z] [18]
⏷ Show the Full List of 192 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Hydroxypropyl betadex E00697 Not Available Complexing agent; Modified-release agent; penetration agent; Solubilizing agent; Tonicity agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cladribine 10mg tablet 10mg Tablet Oral
Cladribine 1mg/ml injectable 1mg/ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4799).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
8 Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
9 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
11 Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186.
12 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detect Prev. 2004;28(6):433-42. doi: 10.1016/j.cdp.2004.08.001.
13 Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J. 2001 Nov 1;359(Pt 3):537-46. doi: 10.1042/0264-6021:3590537.
14 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
15 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
16 Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br J Nutr. 2012 Mar;107(6):781-90. doi: 10.1017/S0007114511003631. Epub 2011 Aug 1.
17 In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004 Mar;18(3):521-9. doi: 10.1038/sj.leu.2403253.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Cerner Multum, Inc. "Australian Product Information.".
20 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
21 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
23 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
24 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
26 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
27 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]